{"id":352561,"date":"2025-11-03T12:19:11","date_gmt":"2025-11-03T12:19:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/352561\/"},"modified":"2025-11-03T12:19:11","modified_gmt":"2025-11-03T12:19:11","slug":"kimberly-clark-to-acquire-kenvue","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/352561\/","title":{"rendered":"Kimberly-Clark to acquire Kenvue"},"content":{"rendered":"

Trading information on Kenvue Inc., a consumer-health business spun off from Johnson & Johnson, is displayed on a screen during the company’s IPO at the New York Stock Exchange in New York City, May 4, 2023.<\/p>\n

Brendan Mcdermid | Reuters<\/p>\n

Kimberly-Clark<\/a> said on Monday it will buy Tylenol-maker Kenvue<\/a> in a cash-and-stock deal valued at about $48.7 billion, to create one of the biggest consumer health goods companies in the United States.<\/p>\n

Shares of Kenvue were up 18% in premarket trading, while Kimberly-Clark’s shares were down 12.5%.<\/p>\n

Kenvue has been under a strategic review, leadership shake-up, and mounting litigation risks. It came under fresh scrutiny following President Donald Trump’s comments linking its popular pain medicine Tylenol to autism.<\/p>\n

The deal will bring together brands including Neutrogena, Huggies and Kleenex under a consumer health and personal care company with expected combined annual revenues of roughly $32 billion.<\/p>\n

Sources in June told Reuters the strategic review of its operations could include a sale or breakup of the company that had been spun off from healthcare conglomerate Johnson & Johnson<\/a> in 2023.<\/p>\n

Kenvue’s shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held. That implies a per-share deal value of $21.01, or an equity value of $40.32 billion, according to Reuters calculations.<\/p>\n","protected":false},"excerpt":{"rendered":"Trading information on Kenvue Inc., a consumer-health business spun off from Johnson & Johnson, is displayed on a…\n","protected":false},"author":3,"featured_media":352562,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[9167,64,81,9166,1876,112087,69379,152,67,132,68],"class_list":{"0":"post-352561","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-breaking-news-business","9":"tag-business","10":"tag-business-news","11":"tag-health-care-industry","12":"tag-johnson-johnson","13":"tag-kenvue-inc","14":"tag-kimberly-clark-corp","15":"tag-pharmaceuticals","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115485734684122701","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/352561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=352561"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/352561\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/352562"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=352561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=352561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=352561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}